Proactive Investors - Run By Investors For Investors

Outlook Therapeutics over 50% enrolled in clinical study to treat wet AMD

Outlook Therapeutics (NASDAQ:OTLK) CEO Larry Kenyon sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

View full OTLK profile View Profile

Outlook Therapeutics Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use